Cost-effectiveness of edaravone dexborneol versus dl-3-n-butylphthalide for the treatment of acute ischemic stroke: a Chinese health care perspective

Edaravone dexborneol and dl-3-n-butylphthalide are two innovative brain cytoprotective drugs from China that have been approved and widely prescribed for acute ischemic stroke, and the cost of the two drugs ar...

Source: BMC Public Health - February 12, 2024 Category: Consumer Health News Authors: Jianchun Li, Weihan Cao, Fei Zhao and Pengfei Jin Tags: Research Source Type: research